Relevance of Fluorinated Ligands to the Design of Metallodrugs for Their Potential Use in Cancer Treatment

José C. Páez-Franco; Miriam R. Zermeño-Ortega; Carmen Myriam de la O-Contreras; Daniel Canseco-González; Jesus R. Parra-Unda; Alcives Avila-Sorrosa; Raúl G. Enríquez; Juan M. Germán-Acacio; David Morales-Morales

doi:10.3390/pharmaceutics14020402

Relevance of Fluorinated Ligands to the Design of Metallodrugs for Their Potential Use in Cancer Treatment

José C. Páez-Franco, Miriam R. Zermeño-Ortega, Carmen Myriam de la O-Contreras, Daniel Canseco-González, Jesus R. Parra-Unda, Alcives Avila-Sorrosa, Raúl G. Enríquez, Juan M. Germán-Acacio, David Morales-Morales

Escuela Nacional de Ciencias Biológicas (ENCB)

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

8 Citas (Scopus)

Resumen

Fluorination of pharmaceutical agents has afforded crucial modifications to their pharmacological profiles, leading to important advances in medicinal chemistry. On the other hand, metallodrugs are considered to be valuable candidates in the treatment of several diseases, albeit with the caveat that they may exhibit pharmacological disadvantages, such as poor water solubility, low bioavailability and short circulating time. To surmount these limitations, two approaches have been developed: one based on the design of novel metallodrug-delivering carriers and the other based on optimizing the structure of the ligands bound to the metal center. In this context, fluorination of the ligands may bring beneficial changes (physicochemical and biological) that can help to elude the aforementioned drawbacks. Thus, in this review, we discuss the use of fluorinated ligands in the design of metallodrugs that may exhibit potential anticancer activity.

Idioma original	Inglés
Número de artículo	402
Publicación	Pharmaceutics
Volumen	14
N.º	2
DOI	https://doi.org/10.3390/pharmaceutics14020402
Estado	Publicada - feb. 2022

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.3390/pharmaceutics14020402

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

Páez-Franco, J. C., Zermeño-Ortega, M. R., de la O-Contreras, C. M., Canseco-González, D., Parra-Unda, J. R., Avila-Sorrosa, A., Enríquez, R. G., Germán-Acacio, J. M., & Morales-Morales, D. (2022). Relevance of Fluorinated Ligands to the Design of Metallodrugs for Their Potential Use in Cancer Treatment. Pharmaceutics, 14(2), Artículo 402. https://doi.org/10.3390/pharmaceutics14020402

@article{3499978d373e4d6dbb0d94d50f81d116,

title = "Relevance of Fluorinated Ligands to the Design of Metallodrugs for Their Potential Use in Cancer Treatment",

abstract = "Fluorination of pharmaceutical agents has afforded crucial modifications to their pharmacological profiles, leading to important advances in medicinal chemistry. On the other hand, metallodrugs are considered to be valuable candidates in the treatment of several diseases, albeit with the caveat that they may exhibit pharmacological disadvantages, such as poor water solubility, low bioavailability and short circulating time. To surmount these limitations, two approaches have been developed: one based on the design of novel metallodrug-delivering carriers and the other based on optimizing the structure of the ligands bound to the metal center. In this context, fluorination of the ligands may bring beneficial changes (physicochemical and biological) that can help to elude the aforementioned drawbacks. Thus, in this review, we discuss the use of fluorinated ligands in the design of metallodrugs that may exhibit potential anticancer activity.",

keywords = "Anticancer activity, Cancer, Coordination complexes, Cytotoxicity, Fluorinated ligands, Metallodrugs, Organometallics",

author = "P{\'a}ez-Franco, {Jos{\'e} C.} and Zerme{\~n}o-Ortega, {Miriam R.} and {de la O-Contreras}, {Carmen Myriam} and Daniel Canseco-Gonz{\'a}lez and Parra-Unda, {Jesus R.} and Alcives Avila-Sorrosa and Enr{\'i}quez, {Ra{\'u}l G.} and Germ{\'a}n-Acacio, {Juan M.} and David Morales-Morales",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = feb,

doi = "10.3390/pharmaceutics14020402",

language = "Ingl{\'e}s",

volume = "14",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "Multidisciplinary Digital Publishing Institute",

number = "2",

}

Páez-Franco, JC, Zermeño-Ortega, MR, de la O-Contreras, CM, Canseco-González, D, Parra-Unda, JR, Avila-Sorrosa, A, Enríquez, RG, Germán-Acacio, JM & Morales-Morales, D 2022, 'Relevance of Fluorinated Ligands to the Design of Metallodrugs for Their Potential Use in Cancer Treatment', Pharmaceutics, vol. 14, n.º 2, 402. https://doi.org/10.3390/pharmaceutics14020402

TY - JOUR

T1 - Relevance of Fluorinated Ligands to the Design of Metallodrugs for Their Potential Use in Cancer Treatment

AU - Páez-Franco, José C.

AU - Zermeño-Ortega, Miriam R.

AU - de la O-Contreras, Carmen Myriam

AU - Canseco-González, Daniel

AU - Parra-Unda, Jesus R.

AU - Avila-Sorrosa, Alcives

AU - Enríquez, Raúl G.

AU - Germán-Acacio, Juan M.

AU - Morales-Morales, David

PY - 2022/2

Y1 - 2022/2

N2 - Fluorination of pharmaceutical agents has afforded crucial modifications to their pharmacological profiles, leading to important advances in medicinal chemistry. On the other hand, metallodrugs are considered to be valuable candidates in the treatment of several diseases, albeit with the caveat that they may exhibit pharmacological disadvantages, such as poor water solubility, low bioavailability and short circulating time. To surmount these limitations, two approaches have been developed: one based on the design of novel metallodrug-delivering carriers and the other based on optimizing the structure of the ligands bound to the metal center. In this context, fluorination of the ligands may bring beneficial changes (physicochemical and biological) that can help to elude the aforementioned drawbacks. Thus, in this review, we discuss the use of fluorinated ligands in the design of metallodrugs that may exhibit potential anticancer activity.

AB - Fluorination of pharmaceutical agents has afforded crucial modifications to their pharmacological profiles, leading to important advances in medicinal chemistry. On the other hand, metallodrugs are considered to be valuable candidates in the treatment of several diseases, albeit with the caveat that they may exhibit pharmacological disadvantages, such as poor water solubility, low bioavailability and short circulating time. To surmount these limitations, two approaches have been developed: one based on the design of novel metallodrug-delivering carriers and the other based on optimizing the structure of the ligands bound to the metal center. In this context, fluorination of the ligands may bring beneficial changes (physicochemical and biological) that can help to elude the aforementioned drawbacks. Thus, in this review, we discuss the use of fluorinated ligands in the design of metallodrugs that may exhibit potential anticancer activity.

KW - Anticancer activity

KW - Cancer

KW - Coordination complexes

KW - Cytotoxicity

KW - Fluorinated ligands

KW - Metallodrugs

KW - Organometallics

UR - http://www.scopus.com/inward/record.url?scp=85124837319&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics14020402

DO - 10.3390/pharmaceutics14020402

M3 - Artículo de revisión

C2 - 35214133

AN - SCOPUS:85124837319

SN - 1999-4923

VL - 14

JO - Pharmaceutics

JF - Pharmaceutics

IS - 2

M1 - 402

ER -

Relevance of Fluorinated Ligands to the Design of Metallodrugs for Their Potential Use in Cancer Treatment

Resumen

ODS de las Naciones Unidas

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto